MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

Search

Danaher Corp

Abierto

SectorSanidad

241.4 1.66

Resumen

Variación precio

24h

Actual

Mínimo

235.49

Máximo

242.37

Métricas clave

By Trading Economics

Ingresos

353M

908M

Ventas

117M

6.1B

P/B

Media del Sector

48.558

89.037

BPA

1.89

Rentabilidad por dividendo

0.51

Margen de beneficios

15.001

Empleados

61,000

EBITDA

428M

1.8B

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+13.27% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.51%

2.18%

Próximas Ganancias

28 ene 2026

Fecha Próximo Dividendo

30 ene 2026

Próxima Fecha de Ex Dividendo

27 mar 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

19B

169B

Apertura anterior

239.74

Cierre anterior

241.4

Noticias sobre sentimiento de mercado

By Acuity

31%

69%

98 / 360 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Danaher Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 ene 2026, 17:13 UTC

Ganancias

Danaher Forecasts 4Q Revenue at High-End of Guidance on Bioprocessing Strength -- Update

21 oct 2025, 17:41 UTC

Ganancias

Danaher 3Q Earnings Rise; Pharma R&D Spend Expected to Rebound -- Update

21 oct 2025, 10:28 UTC

Ganancias

Danaher 3Q Sales and Profit Rise on Bioprocessing Momentum

22 jul 2025, 11:32 UTC

Ganancias

Danaher Posts Lower 2Q Profit, Names Next CFO -- Update

22 jul 2025, 10:42 UTC

Ganancias

Danaher Posts Higher 2Q Sales, Lower Profit

22 abr 2025, 10:34 UTC

Ganancias

Danaher 1Q Results Decline But Top Estimates

14 ene 2026, 20:30 UTC

Charlas de Mercado
Ganancias

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

21 oct 2025, 10:02 UTC

Ganancias

Danaher 3Q Adjusted Core Revenue Rose 3% >DHR

21 oct 2025, 10:01 UTC

Ganancias

Danaher Sees 2025 Adjusted Core Revenue Up Low-Single Digits >DHR

21 oct 2025, 10:01 UTC

Ganancias

Danaher Backs 2025 View of Adj EPS $7.70-Adj EPS $7.80 >DHR

21 oct 2025, 10:00 UTC

Ganancias

Danaher 3Q Operating Cash Flow $1.7B, Free Cash Flow $1.4B >DHR

21 oct 2025, 10:00 UTC

Ganancias

Danaher 3Q Net $908M >DHR

21 oct 2025, 10:00 UTC

Ganancias

Danaher 3Q Sales $6.05B >DHR

21 oct 2025, 10:00 UTC

Ganancias

Danaher 3Q Adj EPS $1.89 >DHR

21 oct 2025, 10:00 UTC

Ganancias

Danaher 3Q EPS $1.27 >DHR

22 jul 2025, 10:03 UTC

Ganancias

Danaher Had Seen 2025 Adjusted EPS $7.60-$7.75 >DHR

22 jul 2025, 10:03 UTC

Ganancias

Danaher Raises 2025 View To Adj EPS $7.70-Adj EPS $7.80 >DHR

22 jul 2025, 10:02 UTC

Ganancias

Danaher Still Sees 2025 Core Revenue Up About 3% >DHR

22 jul 2025, 10:01 UTC

Ganancias

Danaher Sees 3Q Core Revenue Up Low-Single Digits >DHR

22 jul 2025, 10:00 UTC

Ganancias

Danaher 2Q Operating Cash Flow $1.3B, Free Cash Flow $1.1B >DHR

22 jul 2025, 10:00 UTC

Ganancias

Danaher 2Q Net $555M >DHR

22 jul 2025, 10:00 UTC

Ganancias

Danaher 2Q Sales $5.9B >DHR

22 jul 2025, 10:00 UTC

Ganancias

Danaher 2Q Adj EPS $1.80 >DHR

22 jul 2025, 10:00 UTC

Ganancias

Danaher 2Q EPS 77c >DHR

22 jul 2025, 09:34 UTC

Acciones populares

Stocks to Watch Tuesday: Coca-Cola, GM, AstraZeneca, NXP -- WSJ

14 jul 2025, 16:12 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

22 abr 2025, 10:02 UTC

Ganancias

Danaher Still Sees 2025 Adjusted Core Revenue Up About 3% >DHR

22 abr 2025, 10:02 UTC

Ganancias

Danaher Sees 2025 Adj EPS $7.60-Adj EPS $7.75 >DHR

22 abr 2025, 10:02 UTC

Ganancias

Danaher Sees 2Q Adjusted Core Revenue Up Low-Single Digits >DHR

22 abr 2025, 10:01 UTC

Ganancias

Danaher: Macro Backdrop Has Become More Dynamic Since Start of Year >DHR

Comparación entre iguales

Cambio de precio

Danaher Corp previsión

Precio Objetivo

By TipRanks

13.27% repunte

Estimación a 12 Meses

Media 265.42 USD  13.27%

Máximo 310 USD

Mínimo 240 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Danaher Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

13

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

189.8851 / 196.5Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Neutral Evidence

Sentimiento

By Acuity

98 / 360 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
help-icon Live chat